EMVision Medical Devices (EMV) Q2 2026 TU earnings summary

Executive summary

• Seven leading stroke hospitals are now activated and recruiting for the emu™ Pivotal (Validation) Trial, with additional sites in New York and Houston enhancing recruitment and access to diverse patient populations.

• Preparations for a grant-funded Regional Benefits Study are underway, with the first $0.4 million milestone payment received and study launch planned for 2H CY2026.

• Multiple pre-hospital feasibility and usability studies for the First Responder device are advancing across mobile stroke units, aeromedical, and road ambulance settings.

• Strong international engagement, including participation at MEDICA 2025 and exploratory clinical collaborations in Europe, supports future commercial pathways.

Financial highlights

• Cash reserves stood at $17.5 million as of 31 December 2025.

• Net operating cash outflows for the quarter were $2.564 million, with R&D expenditure at $0.578 million, staff costs at $1.921 million, and corporate administration costs at $0.606 million.

• $2.0 million was raised from an oversubscribed Share Purchase Plan during the quarter.

• Additional non-dilutive funding of $7.0 million remains available from grant programs, and an R&D tax incentive rebate (FY24: $2.1 million) is expected next quarter.

Outlook and guidance

• Pivotal Trial enrolment is on track for completion in the first half of calendar year 2026.

• The Regional Benefits Study is expected to activate in the second half of 2026, generating real-world clinical and health-economic evidence.

• Preliminary findings from the aeromedical study will be presented at the International Stroke Conference in February 2026.